Clinical breast cancer最新文献

{"title":"A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer","authors":"Stefania Morganti ,&nbsp;Xiangying Chu ,&nbsp;Tarah J. Ballinger ,&nbsp;Nisha Unni ,&nbsp;Sarah Sinclair ,&nbsp;Robert Wesolowski ,&nbsp;Alyssa M. Pereslete ,&nbsp;Paulina Lange ,&nbsp;Nabihah Tayob ,&nbsp;Nancy U. Lin ,&nbsp;Jose P. Leone ,&nbsp;Ian E. Krop ,&nbsp;Sara M. Tolaney ,&nbsp;Heather A. Parsons","doi":"10.1016/j.clbc.2025.05.009","DOIUrl":"10.1016/j.clbc.2025.05.009","url":null,"abstract":"<div><h3>Background</h3><div>Most HER2-positive breast cancers co-express estrogen receptor (ER). Given crosstalk between HER2 and ER signaling pathways, dual blockade may be beneficial.</div></div><div><h3>Methods</h3><div>In this randomized, open-label, phase 2 clinical trial, patients with ER-positive (ER ≥ 10%), HER2-positive metastatic breast cancer were randomized (1:1) to neratinib (240 mg daily) or the same dose of neratinib with fulvestrant. Any number of prior therapies was allowed; prior trastuzumab, pertuzumab and trastuzumab emtansine were required. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), overall response rate, and duration of response. Exploratory objectives included the identification of predictive biomarkers via circulating tumor DNA (ctDNA).</div></div><div><h3>Results</h3><div>Of 21 patients enrolled, 18 were evaluable for outcomes and safety (neratinib-fulvestrant arm, <em>n</em> = 8; neratinib-only arm, <em>n</em> = 10). The study was closed before completing enrollment due to slow accrual. Median PFS did not differ between treatment arms (2.79 months with neratinib-fulvestrant versus 5.55 months with neratinib only [HR 0.94; 95% CI, 0.24-3.64; <em>P</em> = .98]). Grade 3 adverse events occurred in 1 (12.5%) patient in the neratinib-fulvestrant arm and 6 (60%) patients in the neratinib-only arm, with diarrhea being the most frequent. Median OS did not differ between the 2 arms (<em>P</em> = .91). Clearance of ctDNA was associated with PFS and OS.</div></div><div><h3>Conclusions</h3><div>The combination of neratinib and fulvestrant is safe and tolerable. Due to early study closure, this study was underpowered to detect the benefit of adding fulvestrant to neratinib. Chemotherapy-free regimens targeting ER and HER2 warrant further investigation, along with prospective studies investigating ctDNA dynamics may guide treatment switch.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 6","pages":"Pages 566-574.e2"},"PeriodicalIF":2.9,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study","authors":"Soraia Lobo-Martins ,&nbsp;Veronique Debien ,&nbsp;Elisa Agostinetto ,&nbsp;Marianna Sirico ,&nbsp;Giselle de Souza Carvalho ,&nbsp;Flavia Jacobs ,&nbsp;Chiara Molinelli ,&nbsp;Renata Colombo Bonadio ,&nbsp;Pedro Bergmann ,&nbsp;Cristiano de Pádua Souza ,&nbsp;Laura Testa ,&nbsp;Marina Nishimuni ,&nbsp;André João Rossi ,&nbsp;Gabriel Kamei Guimarães ,&nbsp;Michel Moreau ,&nbsp;Ugo De Giorgi ,&nbsp;José Bines ,&nbsp;Armando Santoro ,&nbsp;Donatienne Taylor ,&nbsp;Francois P. Duhoux ,&nbsp;Evandro de Azambuja","doi":"10.1016/j.clbc.2025.05.002","DOIUrl":"10.1016/j.clbc.2025.05.002","url":null,"abstract":"<div><h3>Background</h3><div>An anthracycline-free regimen of adjuvant paclitaxel and trastuzumab is the standard-of-care for patients with HER2-positive (HER2+) early breast cancer (eBC) with tumors ≤20 mm, node-negative tumors, based on the results of a single-arm phase II trial. We investigated the outcomes of this regimen in a real-world (RW) setting.</div></div><div><h3>Methods</h3><div>This retrospective, international RW study included patients with stage I HER2+ eBC treated with the APT regimen (tumors of 5-20 mm, node-negative (N0 or Nmi) and no previous history of BC). Data on demographics, tumor characteristics, treatments, and survival were extracted from medical records from 11 hospitals in Belgium, Italy, and Brazil. The primary endpoint was 5-year RW disease-free survival (rwDFS), and secondary was RW overall survival (rwOS).</div></div><div><h3>Results</h3><div>From January 2014 to July 2018, 252 patients were identified. The median age was 57.9 years, and 69.8% were postmenopausal women at diagnosis. Most tumors (88.1%) had ductal histology and were estrogen receptor-positive (81.7%). The median tumor size was 12 mm (Interquartile [IQR] 9.0-15.0). Breast-conserving surgery was performed in 77.8%, and radiotherapy was administered in 76.1% of patients. Median follow-up was 5.8 years (IQR 5.0-6.8). In total, 13 events were observed: 4 locoregional, 2 distant (1 bone and 1 visceral) and 7 second nonbreast primary malignancies. The 5-year rwDFS rate was 95.3% (95% Confidence Interval (CI) 92.7-98.1), and rwOS was 97.9% (95% CI 96.2-99.7).</div></div><div><h3>Conclusion</h3><div>Our RW data supports the effectiveness of the APT regimen, showing excellent 5-year survival outcomes in selected patients with low-risk HER2+ eBC.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 7","pages":"Pages e945-e953.e1"},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Safe Use of 125I-Seeds as a Surgical Localization Technique for Breast Cancer Patients During Breastfeeding and Close Contact With an Infant","authors":"Eva Heeling ,&nbsp;Jeroen B. van de Kamer ,&nbsp;Annemarie Bruining ,&nbsp;Jip M.E. Pluim ,&nbsp;Marie-Jeanne T.F.D. Vrancken Peeters ,&nbsp;Christianne A.R. Lok ,&nbsp;Iris M.C. van der Ploeg","doi":"10.1016/j.clbc.2025.05.008","DOIUrl":"10.1016/j.clbc.2025.05.008","url":null,"abstract":"<div><h3>Purpose</h3><div>Currently, Dutch hospitals advise limiting mother-infant contact to 1 hour per day if an ¹²⁵I-seed is implanted for breast cancer surgery, possibly affecting bonding and the child's cognitive and behavioral development. By quantifying radiation exposure from an ¹²⁵I-seed to the infant through breastfeeding and close contact, we aim to provide evidence-based recommendations for clinical practice.</div></div><div><h3>Methods</h3><div>We modelled the radiation exposure to an infant due to contact with a mother or patient with an ¹²⁵I-seed in situ in the breast, assessing both the ipsilateral and contralateral breast at different time periods (14 days, 90 days, and 180 days). The radiation exposure to the infant was considered safe as long as it remained below the threshold of 1 mSv.</div></div><div><h3>Results</h3><div>When an ¹²⁵I-seed is surgical removed within 14 days after insertion, daily contact on the contralateral contact is safe (up to 24 hours a day). When ipsilateral contact is included, the maximum duration adjusts to 19 hours per day contralateral combined with 5 hours per day ipsilateral. When the ¹²⁵I-seed remains in situ for a longer period, such as during primary systemic treatment (PST) (e.g., 90 or 180 days), contact is possible with certain limitations.</div></div><div><h3>Conclusion</h3><div>Contralateral close contact (including breastfeeding) with an infant &lt; 1 year of age is safe in case of breast cancer and an ¹²⁵I-seed in situ in the breast. Short moments of ipsilateral contact are safe, even for a longer period of 180 days.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 7","pages":"Pages 634-642.e4"},"PeriodicalIF":2.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Association between Body Mass Indices and the 21-Gene Recurrence Score: A Systematic Review and Network Meta-Analysis","authors":"Ciara Hunt ,&nbsp;Matthew G Davey ,&nbsp;Ryan Wilson ,&nbsp;Juliette Buckley ,&nbsp;Bridget Anne Merrigan ,&nbsp;Chwanrow Baban ,&nbsp;Shona Tormey","doi":"10.1016/j.clbc.2025.05.006","DOIUrl":"10.1016/j.clbc.2025.05.006","url":null,"abstract":"<div><h3>Background</h3><div>Preconceptions exist regarding the association between obesity and the propensity to develop estrogen receptor positive (ER+) cancer. There is limited data assessing the impact of body mass index (BMI) on 21-gene recurrence score (RS) results.</div></div><div><h3>Aim</h3><div>To perform a systematic review and network meta-analysis to assess whether increased BMI is associated with low RS in estrogen receptor positive (ER+) breast cancer.</div></div><div><h3>Methods</h3><div>A systematic review was performed as per PRISMA guidelines. Descriptive statistics were used as appropriate. Meta-analyses were performed using the Review Manager v5.4 and NMA performed using shiny.</div></div><div><h3>Results</h3><div>6 studies with 3523 patients were included. The mean age was 61 years and mean RS was 16.6 and BMI was 25.8_. When applying traditional RS cut-offs 66.4% of patients had a RS &lt; 18 (3529 out of 5312), 27.6% had RS 18-30 (1466 out of 5412) and 6.0% had a RS of &gt; 30 (317 out of 5312). At meta-analysis, patients with RS 18-30 (risk ratio (RR): 1.15, 95% confidence interval (CI), 0.91-1.46) and RS &gt; 30 (RR: 1.03 95% CI, 0.79-1.35) were not associated with lower BMI. When applying TAILORx cut-offs, 24.2% of patients had a RS &lt; 11 (996 out of 4124), 63.1% had a RS 11-25 (2604 out of 4124) and 12.7% had a RS &gt; 25 (524 out of 4124). At meta-analysis, patients with RS 11-25 (RR: 1.57, 95% CI, 0.77-3.75) and RS &gt; 25 (RR: 1.58, 95% CI, 0.71-3.77) were also not associated with lower BMI.</div></div><div><h3>Conclusion</h3><div>This study failed to identify a significant association between BMI and RS group.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 6","pages":"Pages e779-e786.e2"},"PeriodicalIF":2.9,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial","authors":"Cazzaniga Marina Elena ,&nbsp;Pepe Francesca Fulvia ,&nbsp;Rossi Emanuela ,&nbsp;Coltelli Luigi ,&nbsp;Beano Alessandra ,&nbsp;Valerio Maria Rosaria ,&nbsp;Ferro Antonella ,&nbsp;Zustovich Fable ,&nbsp;Moretti Gabriella ,&nbsp;Toniolo Davide ,&nbsp;Cordani Nicoletta ,&nbsp;Galimberti Stefania ,&nbsp;Capici Serena","doi":"10.1016/j.clbc.2025.05.003","DOIUrl":"10.1016/j.clbc.2025.05.003","url":null,"abstract":"<div><h3>Background and Purpose</h3><div>CDK 4/6 inhibitors with ET are the recommended choice as 1st-line therapy in HR+/HER2- MBC patients, however ET alone could remain an option for some of them. HERMIONE-7 is a multicenter, single-arm, Phase II study, aimed to evaluate Abemaciclib 150 mg BID + AIs, in patients who progressed on 1st line Fulvestrant.</div></div><div><h3>Materials and Methods</h3><div>Primary aim was the efficacy of Abemaciclib + AIs in terms of Clinical Benefit Rate (CBR), secondary aims were Time to Progression (TTP), Overall Response Rate (ORR), duration of response (DOR), and safety.</div></div><div><h3>Results</h3><div>From April 2020 to January 2022, we enrolled 31 patients. Median age was 72 years (range 47-86), 55% had &lt; 2 comorbidities, mainly hypertension (12, 38.7%). Clinical Benefit Rate was 69% (95% CI, 49-85) and ORR was 21% (95%CI, 8-40). 1-year TTP and OS rates were 53.8% (95% CI, 38.6-74.9%) and 69.5% (95% CI, 54.8%-88.5%), respectively. Main adverse events remain diarrhea (80.6%), fatigue (54.8%) and nausea (35.5%), 3 patients (10.7%) had non drug-related fatal events.</div></div><div><h3>Conclusions</h3><div>HERMIONE-7 study showed that 2nd-line treatment with Abemaciclib + AIs is a feasible option in MBC patients who progressed on Fulvestrant in 1st-line setting and could be an alternative especially in terms of optimizing the cost-benefit ratio in some Countries.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 6","pages":"Pages 560-565.e2"},"PeriodicalIF":2.9,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Construction of a New Prognostic Model of Breast Cancer and the Exploration of Drug Sensitivity Based on Machine Learning for Glycosylation-Related Genes","authors":"Jia-Ning Zhang ,&nbsp;Xi-Rui Zhou ,&nbsp;Zi-Lu Yi ,&nbsp;Xin-Yu Tian ,&nbsp;Hong Liu","doi":"10.1016/j.clbc.2025.05.004","DOIUrl":"10.1016/j.clbc.2025.05.004","url":null,"abstract":"<div><h3>Aims</h3><div>Breast cancer has become the number 1 killer threatening women's health. In recent years, glycosylation modification has played an increasingly important role in tumor progression. The aim of this study was to explore the key genes that may be involved in glycosylation modification, establish prognostic models, and further explore their biological functions.</div></div><div><h3>Methods</h3><div>Using data from TCGA and GEO databases, differentially expressed genes (DEGs) were identified. Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted to characterize the functions of the DEGs. LASSO regression analysis was performed to narrow down hub genes. Additionally, single-cell analysis, protein-protein interaction (PPI) network analysis, immune correlation analysis, drug sensitivity analysis, and molecular docking were carried out to investigate the functions of these hub genes.</div></div><div><h3>Results</h3><div>Initially, we identified 110 differentially expressed prognostic genes, among which 89 were potentially associated with glycosylation modification. Enrichment analysis revealed their involvement in oxytocin signaling, chemical carcinogen-DNA adduct formation, and C-type lectin receptor pathways. LASSO regression (Least Absolute Shrinkage and Selection Operator) analysis further refined the selection to 24 hub genes, which exhibited specific genetic interactions. Notably, the expression levels of these genes showed significant associations with various immune cells. Drug sensitivity analysis of the hub genes highlighted methotrexate as a potential therapeutic candidate. Finally, molecular docking demonstrated strong binding affinities between the target receptors and ligands.</div></div><div><h3>Conclusions</h3><div>In conclusion, we screened glycosylation-related Hub genes, constructed prognostic models, explored their biological functions, and proposed new insights for diagnosing and treating breast cancer.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 6","pages":"Pages e756-e764"},"PeriodicalIF":2.9,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Analysis of Hormone Receptors and HER2 in Breast Squamous Cell Carcinoma: A Matched Study Using the SEER Database","authors":"Miao Wang ,&nbsp;Kehua Hu ,&nbsp;Yanping Gao ,&nbsp;Xiaowan Guo ,&nbsp;Jie Li ,&nbsp;Yaoxiong Xia ,&nbsp;Hui Qiu ,&nbsp;Qiuji Wu","doi":"10.1016/j.clbc.2025.04.015","DOIUrl":"10.1016/j.clbc.2025.04.015","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype.</div></div><div><h3>Materials and Methods</h3><div>We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors.</div></div><div><h3>Results</h3><div>BSCC patients were older (&gt; 60 years: 60.6% vs. 52.4%, <em>P</em> = .037), had higher TNBC incidence (64.0% vs. 12.2%, <em>P</em> = .001), and higher metastasis rates (48% vs. 33.3%, <em>P</em> &lt; .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, <em>P</em> = .009). BSCC patients had worse OS and CSS (<em>P</em> &lt; .001). In non-TNBC, BSCC showed poor survival before and after PSM (<em>P</em> &lt; .05). In TNBC, BSCC had worse OS than BIDC (<em>P</em> &lt; .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (<em>P</em> &lt; .001), while receptor subtype was not (<em>P &gt; .</em>05).</div></div><div><h3>Conclusion</h3><div>BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 6","pages":"Pages e739-e749.e2"},"PeriodicalIF":2.9,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved Breast Cancer Detection with Artificial Intelligence in a Real-World Digital Breast Tomosynthesis Screening Program.","authors":"Joshua A Nepute, Meridith Peratikos, Alicia Y Toledano, John P Salvas, Haley Delks, Julie L Shisler, Jeffrey W Hoffmeister, Colleen M Madden","doi":"10.1016/j.clbc.2025.05.007","DOIUrl":"https://doi.org/10.1016/j.clbc.2025.05.007","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study is to compare radiologists' breast cancer screening performance before and after the implementation of an artificial intelligence (AI) detection system for digital breast tomosynthesis (DBT).</p><p><strong>Materials and methods: </strong>This retrospective study included 4 radiologists reading DBT screening mammograms across 3 clinical sites during 2 distinct time periods. The pre-AI time period from September 1, 2018 to August 31, 2019 included 10,322 standard DBT interpretations with a computer-aided detection system. The post-AI from January 1 to March 18, 2020 and May 4 to December 31, 2020 included 6,407 DBT interpretations with concurrent use of a deep learning AI support system. Endpoints included cancer detection rate (CDR), abnormal interpretation rate (AIR), and positive predictive values for cancer among screenings with abnormal interpretation (PPV1) and biopsies performed (PPV3). Estimates and 95% confidence intervals (CIs) for each radiologist were calculated for each time point and the difference across time periods.</p><p><strong>Results: </strong>The CDR per 1000 exams increased from 3.7 without AI to 6.1 with AI (difference 2.4, P = .008, 95% CI: 0.6, 4.2). The AIR was 8.2% without AI and 6.5% with AI (difference -1.7, P < .001, 95% CI: -2.5, -0.8). The PPV1 increased from 4.2% to 8.8% with AI implementation (difference 4.6, P < .001, 95% CI: 3.0, 6.3) and PPV3 increased from 32.3% to 56.5% with AI support (difference 24.2, P = .033, 95% CI: 2.0, 46.4).</p><p><strong>Conclusion: </strong>Real-world interpretation of DBT after implementation of an AI detection system resulted in increased CDR, reduced AIR, and significantly increased PPV1 and PPV3.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolomics Biomarkers for Breast Cancer: An updated perspective","authors":"Christina Jane Vellan ,&nbsp;Vijayakumar Natesan ,&nbsp;Jaime Jacqueline Jayapalan","doi":"10.1016/j.clbc.2025.05.005","DOIUrl":"10.1016/j.clbc.2025.05.005","url":null,"abstract":"<div><div>Breast cancer (BC) remains a significant global health concern, emphasising the need for accurate diagnostic and prognostic tools. Metabolomics, the study of small molecules involved in cellular processes, has emerged as a promising approach for identifying BC biomarkers. This review provides an updated overview of metabolomic biomarkers for BC, focusing on early detection, diagnosis, prognosis prediction, and subtype-specific markers. It covers the various sources of biological samples used in biomarker investigations and common methodologies such as liquid chromatography-mass spectrometry and nuclear magnetic resonance. This review also highlights key classes of metabolites, including amino acids, lipids, and carbohydrates, which exhibit consistent alterations in BC patients and are integral to crucial oncogenic pathways, such as energy metabolism, redox balance, immune modulation, and membrane remodeling. Notably, several metabolite panels have demonstrated high sensitivity and specificity, showing promise for effectively stratifying patients according to tumor subtype. Despite the promising potential of metabolomics, challenges remain in standardizing analytical techniques, validating biomarkers, and integrating metabolomics with other omics approaches. Addressing these will be essential for harnessing the full potential of metabolomics in advancing precision oncology for BC.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 6","pages":"Pages e765-e778"},"PeriodicalIF":2.9,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound Radiomics-Based Machine Learning and SHapley Additive exPlanations Method Predicting Pathological Prognostic Stage in Breast Cancer: A Bicentric and Validation Study","authors":"Lei Chen ,&nbsp;YiXi Su ,&nbsp;Yaoqin Wang ,&nbsp;Yue Yu ,&nbsp;Danfeng Huang ,&nbsp;Meilian Zhang ,&nbsp;Xiaoshuang Chen ,&nbsp;Xu Ye ,&nbsp;Yimi He ,&nbsp;Ensheng Xue ,&nbsp;Liwu Lin ,&nbsp;Zhikui Chen","doi":"10.1016/j.clbc.2025.05.001","DOIUrl":"10.1016/j.clbc.2025.05.001","url":null,"abstract":"<div><h3>Purpose</h3><div>To build and validate ultrasound (US) radiomics-based machine learning (ML) models to predict the pathological prognostic stage of breast cancer (BCa).</div></div><div><h3>Methods</h3><div>We retrospectively included 578 BCa patients from two hospitals (468 and 110 in the training and test sets, respectively). For each patient, the pathological prognostic stage was determined. US radiomics<span> features were extracted, preprocessed, and selected. Five US radiomics-based ML models were built to distinguish between pathological prognostic stage II-III and 0-I groups. The fusion model was built by combining the optimal radiomics model with clinical indicators. Receiver operating characteristic (ROC) curve analysis was applied to evaluate the performance of the models. SHapley Additive exPlanations (SHAP) method was used to interpret the models.</span></div></div><div><h3>Results</h3><div>For each lesion, 1333 US radiomics features were extracted and 11 features were finally selected to build models. The MLP<span> model achieved optimal performance with the AUC of 0.893 and 0.806 in the training and test sets, respectively. The AUC of the fusion model was 0.913 and 0.823 in training and test sets, respectively. The squareroot_glszm_GrayLevelNonUniformity and wavelet-LHH_gldm_DependenceVariance were the most important features of the MLP model and fusion model, respectively.</span></div></div><div><h3>Conclusions</h3><div>US radiomics-based ML is helpful for preoperatively predicting the pathological prognostic stage of BCa, which has potential reference value for making individualized treatment strategies and predicting disease prognosis in clinical practice.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 7","pages":"Pages e954-e967.e6"},"PeriodicalIF":2.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}